A phase 1/2 trial evaluating KSQ-004EX, a novel CRISPR-engineered tumor infiltrating lymphocyte (eTIL) therapy, has dosed its first patient with an advanced solid tumor.
2025
Melanoma patients in England get fast-track access to cancer vaccine
Patients with an advanced type of skin melanoma in England will be given fast-track access to a “revolutionary” new cancer vaccine as part of an NHS trial.
Advanced Melanoma at Diagnosis Associated With Several Patient-Specific Factors
Patients with certain sociodemographic factors are significantly more likely to present with advanced-stage melanoma at diagnosis, including those who live farther from treatment centers, those with Medicaid or without insurance, and those from lower-income households, among other factors. These study findings were published in SKIN.
FDA Backs Darovasertib Phase 3 Trial Design in Uveal Melanoma
Following a successful Type D meeting with the FDA, IDEAYA Biosciences announced a phase 3 registrational trial design to evaluate the safety and efficacy of darovasertib as neoadjuvant therapy for the treatment of patients with primary uveal melanoma.